How to dose BPC-157 + TB-500

In the Body Pharm pen, BPC-157 and TB-500 come dissolved together in a single cartridge, at 50%: 16 mg of each peptide, 32 mg in total. There is one single dial, and the number you set on it is the dose of each peptide: 0.25 mg on the dial is 0.25 mg of BPC-157 plus 0.25 mg of TB-500, which is to say 0.5 mg in total [1]. By construction, the two peptides are always dosed in exactly the same way, by the subcutaneous route, once a day. A typical research schedule sets 0.5 mg on the dial once a day during a four-week loading phase and then drops to 0.25 mg on the dial once a day in maintenance. Handling should be checked against the certificate of analysis (CoA) for the batch [1]. This guide covers the phase-by-phase dosing table, the pen workflow and the cold-chain variables that matter when you are working with two peptides in one and the same cartridge.

This article deals with: the basic daily dosing of both peptides in the loading and maintenance phases; the use of the Body Pharm pen; and which protocol variables (body weight, injection site, duration of the combination) need to be recorded in order to ensure reproducibility.

BPC-157 and TB-500 dosing: the essentials

• The dial sets the dose of each peptide: 0.5 mg on the dial during the four-week loading phase and then 0.25 mg on the dial in maintenance
• The two peptides come dissolved together in a single 16 mg + 16 mg cartridge, so that they necessarily follow one and the same daily schedule
• A single injection a day delivers both peptides: there is nothing to prepare, nothing to mix and nothing to calculate
• Adjustment for body weight, proximity of the injection site and the duration of the combination are unvalidated variables that should be noted in any research protocol
• Neither of the two peptides is authorised as a medicine; all supply is for research purposes only
• Cold-chain discipline (2–8 °C, no freeze-thaw cycles) is every bit as decisive as dose accuracy

Quick reference for basic dosing

Both peptides are dosed identically because they share a cartridge and a dial between them. Both of them remain unauthorised as medicines and fall outside any authorised indication [6].

Research notice

All Body Pharm products are sold solely for the purposes of research and analysis. Not for human consumption.

The protocols, dosing tables and handling guidance in this guide describe parameters that have been published and described by practitioners for in vitro and analytical research contexts. BPC-157 and TB-500 are not authorised as medicines and they have neither an authorised indication nor a dosing standard [6]. None of this constitutes medical advice. For the mechanistic context, consult our BPC-157 vs. TB-500 comparison or review the recovery peptides category.

What BPC-157 and TB-500 are

BPC-157 is a synthetic 15-amino-acid sequence derived from a fragment of the Body Protection Compound identified in human gastric juice. It is studied in preclinical models for its angiogenic signalling, its effects at the tendon-to-bone interface and its modulation of the intestinal barrier. TB-500 is a synthetic analogue covering the active region of thymosin beta-4 (TB-4), a 43-amino-acid peptide studied in models of actin regulation, cell migration and cardiac and dermal wound healing.

They are studied together because their proposed mechanisms act at different spatial scales: BPC-157 acts locally at the injection or injury site, whereas TB-500 distributes systemically. That complementarity, and not redundancy, is the usual justification for combining them in research protocols [3][7].

The bulk of the mechanistic literature on BPC-157 comes from Sikiric and colleagues, from several rodent studies prior to 2024 [2][5]. The pre-2024 pharmacokinetic work in animals describes the plasma half-life of TB-500 as being in the order of hours; the subsequent effects on gene expression are assumed to outlive the circulating peptide, which is why a uniform once-a-day schedule is used in order to sustain the exposure [3][7]. Anyone looking for more recent human data should bear in mind that, at the time of writing, no high-quality peer-reviewed dosing studies from 2024–2025 had appeared in the main databases [7].

For the comparative table of mechanisms, receptor targets and tissue tropism, consult BPC-157 vs. TB-500. Further combination options are in the recovery peptides category.

Why combine BPC-157 with TB-500

The research rationale rests on spatial complementarity: BPC-157 acts as a local tissue-repair signal, whereas TB-500 acts as a systemic signal for cell migration and remodelling. The combination addresses the injury site and the surrounding repair environment in parallel [7]. This is a mechanistic hypothesis extrapolated from separate pieces of preclinical work, not a demonstrated clinical outcome. Up to 2026, no peer-reviewed study has evaluated the two peptides administered together.

The pre-2020 rodent literature on BPC-157 centres on angiogenesis, upregulation of growth factors and effects at the tendon-to-bone interface, at or near the site of administration [2][4][5]. TB-500, as a synthetic analogue of the active region of TB-4, appears in earlier animal models of actin regulation and cell migration, acting systemically once the peptide has distributed through the plasma [3]. One of the peptides drives the local repair cascade; the other sustains the broader cellular machinery on which that repair depends [7].

Local versus systemic action at a glance

For the more detailed receptor-level breakdown, consult BPC-157 vs. TB-500. The neighbouring compounds are in the recovery peptides category.

BPC-157 + TB-500 dosing protocol at a glance

The protocol splits into a four-week loading phase and an open-ended maintenance phase. Because the two peptides share a cartridge and a dial, the number set applies to both of them at once; between phases, only that number changes. All of the figures are extrapolated from pre-2024 practice literature [7] and from pharmacokinetic work in rodents. There is no authorised dosing for either of the two peptides [6].

"Daily" here means seven days a week, not working days only. In the pre-2020 animal studies, both peptides have plasma half-lives in the order of hours, so that continuous once-a-day exposure is the convention for achieving cumulative tissue effects across the whole combination [7].

How to read the dial

The dial sets milligrams and the number set is the dose of each peptide, not the total for the injection. With 0.5 mg set, the injection carries 0.5 mg of BPC-157 and 0.5 mg of TB-500: 1 mg of peptide in total. With 0.25 mg set, 0.25 mg of each and 0.5 mg in total. That is the practical consequence of the cartridge carrying the two peptides dissolved at 50%, with 16 mg of each.

Paired dosing: both peptides, the same amount, daily

The two peptides share a cartridge, so that they are dosed in the same way, the same amount, by the subcutaneous route, once a day, for the whole of the protocol. That is the practical logic of the format: instead of following two different rhythms and two different unit systems, the researcher sets a single number every day. In the loading phase that number is 0.5 mg; in maintenance it drops to 0.25 mg. Both the presumed local angiogenic and growth-factor signalling of BPC-157 and the systemic cell-migration effects of TB-500 benefit from repeated, near-continuous exposure, so that a single shared daily schedule keeps the combination simple and reproducible [7].

The figures are best understood as a reference to start from rather than as a fixed prescription. The citations they rest on are clinical summaries and practitioner guides from 2023 [7]. Researchers should look for peer-reviewed updates from 2025–2026 before fixing their own schedule. For the mechanistic context these figures are based on, consult BPC-157 vs. TB-500. For neighbouring compounds, the recovery peptides category brings together the current range.

Loading phase (weeks 1–4): the doses explained

The loading phase sets 0.5 mg on the dial, which is to say 0.5 mg of each peptide a day. Loading at the high end of the range during the first four weeks reflects the convention in practice of building up the tissue-level effect early on and then holding a lower daily dose once the acute window has closed [7].

BPC-157 at 0.5 mg a day sits at the high end of the 0.25–0.5 mg range described in the pre-2024 practice protocols [7]. TB-500 receives the same amount in the same injection [1]. Both of the figures come from pre-2024 literature and should be treated as potentially out of date until more recent controlled data become available.

No claim of efficacy follows from these figures on their own; they describe exposure, and not outcome. For the mechanistic context of why both peptides are carried together, consult BPC-157 vs. TB-500.

Maintenance phase (from week 5): lowering the daily dose

After the loading phase, the dial drops from 0.5 mg to 0.25 mg once a day: the amount is reduced for both of the peptides at once, because they share a cartridge. The lower maintenance dose reflects the working assumption in the pre-2024 practice literature according to which a smaller continuous daily dose sustains the tissue-level effects once they have been established [7].

The total duration of the protocol varies in the source material. Practice summaries describe loading blocks of 4–6 weeks followed by an extended maintenance, whereas discussions of combinations mention total runs of 8–12 weeks before a washout phase [7]. No controlled study from 2024–2025 defines an optimal endpoint, so that the duration is a practice decision and not an evidence-based criterion [7].

Two practical notes on the step down. First, the 0.25 mg maintenance figure is a convention, not a pharmacokinetically validated dose: it is simply the conservative end of the practice range. Second, anyone who has loaded more intensively may prefer to hold 0.25 mg rather than keep dropping; whatever figure is chosen, it applies equally to the two peptides, because there is only the one dial. For neighbouring compounds during or after the washout phase, consult the recovery peptides category.

Administration: subcutaneous injection guide

Subcutaneous injection at 45° into a raised fold of abdominal or flank tissue is the standard route of administration described for the BPC-157 + TB-500 combination. The pen comes pre-filled, so that at the point of use there is nothing to prepare and nothing to measure.

Site selection follows two lines of reasoning. For systemic action, the tissue of the abdomen or of the flank offers even absorption and makes changing site straightforward. When the research interest centres on a specific tendon, joint or muscle, the BPC-157 literature has studied injection proximity as a variable; in some rodent tendon and ligament models, localised subcutaneous administration near the target tissue is used [2][4]. The effects of TB-500 are described as systemic at the level of gene expression, so that its injection site is mechanistically less tied to the target area [3]. Because the two go in the same injection, the site is chosen with the local component in mind.

Because the combination is dosed daily, the described protocols change site between injections, with a separation of at least 2–3 cm and without repeating the same site on consecutive days, which limits lipohypertrophy and local irritation. The BPC-157 vs. TB-500 guide covers the distinction between localised and systemic action in more detail.

The Body Pharm pen

The Body Pharm pen (2026) is a pre-filled device with a single cartridge in which BPC-157 and TB-500 come dissolved together at 50%: 16 mg of each, 32 mg in total. It has one single dial, marked in milligrams, and the number set is the dose of each peptide. Because up to 2026 there are no peer-reviewed combination studies for these two peptides [7], the protocol treats the pair as a single daily exposure and not as two independent schedules.

Administration sequence as described:

1. Bringing to temperature. The protocols describe taking the pen out of the fridge (2–8 °C) and letting it reach room temperature. According to the reports, cold solution injected straight from the fridge stings and can transiently affect bioavailability at the depot.
2. Fitting the needle. A new disposable pen needle is fitted and the seal is discarded.
3. Priming. The pen is primed with a test selection until a droplet forms at the tip of the needle, which clears the air from the channel.
4. Dialling the dose. The dial is turned to the number that corresponds to the phase according to the table earlier in this guide: 0.5 mg in loading, 0.25 mg in maintenance. That number is the dose of each peptide.
5. Injection. The literature describes subcutaneous administration at 45° into a prepared, dry site.
6. Waiting time. The protocols indicate keeping the needle in place for 5–10 seconds after pressing the plunger fully, so that the depot settles and leakage along the puncture track is avoided.
7. Afterwards and recording. The described sequence ends by replacing the cap, noting down the dose for the day and returning the pen to the fridge within 30 minutes of use.

The single cartridge reduces the researcher's work to a single number each day, which is the whole point of the format. For the rationale for carrying both peptides together rather than separately, consult BPC-157 vs. TB-500.

Aseptic technique checklist

Anyone wanting neighbouring compounds to hand can review the recovery peptides category.

Storage and handling

Store the pen between 2 and 8 °C, protected from light, and never freeze it. Unopened, the shelf life is 24 months. Once the cartridge has been punctured for the first time, the pen is used within 12 months. If you do not have a fridge available, it remains stable at room temperature for a maximum of 30 days, without exceeding 30 °C. Bring the pen up to temperature before injecting. Peptide degradation accelerates with exposure to heat, to ultraviolet light and to repeated freeze-thaw cycles. Cold-chain discipline in storage is every bit as important as dose accuracy. A single freeze-thaw cycle is enough to compromise the integrity of the pen.

At 0.5 mg a day, a cartridge of 16 mg of each peptide covers around 32 days of loading phase. BPC-157 and TB-500 remain unauthorised research compounds without stability data recognised by the authorities [6]. If a pen has exceeded 30 °C or shows cloudiness or particles, discard it rather than adjusting the dose on the basis of presumed degradation.

For the context of why these two peptides are combined, the BPC-157 vs. TB-500 comparison covers the mechanistic split. The broader recovery peptides category carries neighbouring compounds with comparable cold-chain requirements.

Key variables that shape the research protocol

Five variables turn a generic BPC-157 + TB-500 protocol into a specific one: adjustment for body weight, timing of administration, proximity of the injection site, duration of the combination and accompanying compounds. None of them is covered by an authorised dosing standard, because up to 2026 no such standard exists for either of the two peptides [6].

Adjustment for body weight and mcg/kg dosing

Some rodent studies with BPC-157 use a reference dose of 10 mcg/kg. The fixed human range of 0.25–0.5 mg cited in the 2023 clinical summaries is a simplified working figure and not a validated mcg/kg dose curve. No study from 2024–2025 has defined a precise weight-based human dose [7]. A 90 kg researcher and a 60 kg researcher on the same fixed daily dose are not running the same protocol in mcg/kg terms. This variable is usually noted in order to allow comparisons with future studies.

Timing of administration relative to food

BPC-157 has been studied on an empty stomach in rodent gastric models. Whether that timing influences subcutaneous absorption in humans is not characterised in the 2023–2025 literature. Because the combination is dosed daily, researchers usually fix a specific time of day and keep to it.

Proximity of the injection site

Localised subcutaneous administration (near the target tissue) versus systemic administration of BPC-157 produces different results in animal models of tendon and of stomach. TB-500 is administered systemically in any case, since its mechanism involves the circulating activity of TB-4 [3]. Because the two share an injection, the site chosen answers to the local component and that decision is usually noted as a variable.

Duration of the combination

The published practice protocols run for 4–12 weeks, with 4–6 weeks being the most frequent loading window [1][7]. Continued use beyond 12 weeks is not characterised in the available literature. The BPC-157 vs. TB-500 comparison covers the mechanistic arguments for cycling versus indefinite use.

Accompanying compounds

The interactions between BPC-157, TB-500 and other peptides have not been formally studied. The combination with GHK-Cu that is mentioned from time to time in content from US clinics is descriptive and not based on studies [7]. Anyone drawing on the recovery peptides category should treat any multi-peptide combination as an uncharacterised variable, not as an additive certainty.

Frequently Asked Questions

Are two injections needed, one per peptide?

No. The two peptides come dissolved together in the same cartridge, so that a single daily injection delivers both of them [1].

Are BPC-157 and TB-500 dosed in the same amount?

Yes, by construction. The cartridge carries 16 mg of each and there is only one dial, so that the number set is the dose of each peptide: 0.5 mg in loading and 0.25 mg in maintenance, for both at once.

How often are BPC-157 and TB-500 injected?

Once a day, every day, in the loading phase and in the maintenance phase alike. Some older practice material at times described a less frequent dosing of TB-500; the shared-cartridge format instead keeps a uniform daily dose in place for both of them, which makes the cumulative exposure simple and identical across the whole combination [1].

How long does a typical BPC-157 + TB-500 research cycle last?

The published practice protocols run for 4–12 weeks, with 4–6 weeks being the most frequent loading window [1][7]. Continued use beyond 12 weeks is not characterised in the available literature. The rationale for cycling is covered in the BPC-157 vs. TB-500 guide.

Does the pen need to be refrigerated once started?

Yes. Between 2 and 8 °C, protected from light, and used within the 12 months following the first puncture. If no fridge is available, it tolerates up to 30 days at room temperature without exceeding 30 °C [1].

Does the same pen serve for the loading and maintenance phases?

Yes. The same pen covers both phases: the researcher simply sets a lower number in maintenance (0.25 mg instead of 0.5 mg). The device is switched to the lower setting, not refilled.

Is there any research rationale for injecting near the target area rather than at a neutral site?

With BPC-157, localised subcutaneous administration versus systemic administration produces different results in animal models of tendon and of stomach. TB-500 is administered systemically in any case [3]. Anyone comparing options in the recovery peptides category should note the choice of site as a protocol variable.

How much does the pen cost?

The Body Pharm BPC-157 + TB-500 pen (2026) costs €129 per unit.

Getting BPC-157 + TB-500 from Body Pharm

Body Pharm supplies BPC-157 + TB-500 as a research product in a pre-filled pen, a single cartridge with 16 mg of each peptide and a single dial, at €129 per unit. Both compounds are labelled for research only, in keeping with their unauthorised status [6].

Neither of the two peptides holds a marketing authorisation, so that all supply is for laboratory research and not for use in humans [6].

Next steps

Compare the pen with the other options in the recovery peptides category and then go back and read the BPC-157 vs. TB-500 guide to confirm the mechanistic context that this protocol takes for granted. Research protocols usually leave a record of body weight, injection sites, timing of administration and accompanying compounds before a research order is placed. That record helps to refine the approach in future cycles and contributes to the evidence base for these compounds.

Sources

1. Body Pharm dosing protocol for the BPC-157 + TB-500 pen (supplier specification, reviewed October 2026). Supplier research protocol, not a peer-reviewed study.
2. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. pubmed.ncbi.nlm.nih.gov/16583442
3. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. pubmed.ncbi.nlm.nih.gov/22074294
4. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. pubmed.ncbi.nlm.nih.gov/21030672
5. Sikiric P, et al. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018. pubmed.ncbi.nlm.nih.gov/29879879
6. Directive 2001/83/EC, Article 1: definition of a medicinal product by presentation and by function; consolidated text on EUR-Lex. eur-lex.europa.eu — legal basis for a reagent labelled "for research use only" remaining subject to pharmaceutical regulation if it is presented for human use.
7. Clinic and supplier practice literature on BPC-157 and TB-500 (2023–2025), with no published controlled trial. Cited as practice convention, not as evidence.